BioSpace News Archive

Organogenesis Holdings Inc. announced that company management will participate in the Morgan Stanley 20th Annual Global Healthcare Conference, which is being held at the Sheraton New York Times Square Hotel in New York, NY from September 12th-14th.

XOMA Corporation announced its Chairman and Chief Executive Officer, Jim Neal, will present at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12, 2022, at 10:00 AM ET.

Vera Therapeutics, Inc. announced that the Company’s management team will present and participate in one-on-one meetings at the following conferences in September.

SWK Holdings Corporation announced that Jody Staggs, President and Interim CEO of SWK Holdings, will participate in Lake Street Capital’s 6th Annual Best Ideas Growth Conference “BIG6" being held September 14, 2022 in New York City.

Trevi Therapeutics, Inc. announced that Jennifer Good, President and Chief Executive Officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12, 2022, at 10:30 a.m. ET.

Avanos Medical, Inc. announced that Joe Woody, chief executive officer, and Michael Greiner, senior vice president and chief financial officer, will present and participate in an analyst-led fireside chat at the Morgan Stanley Global Healthcare Conference on Wednesday, Sept. 14 at approximately 1:30 p.m., ET.

Zenas BioPharma announced the appointment of Simon Lowry, M.D., as the company’s Chief Medical Officer.

Avadel Pharmaceuticals plc, a biopharmaceutical company focused on transforming medicines to transform lives, announced that members of management will participate in a fireside chat at the H.C. Wainwright Global Investment Conference on Wednesday, September 14 at 11:30 a.m. E.T.

AmMax Bio, Inc. (“AmMax”), a private clinical-stage biopharmaceutical company developing innovative therapeutics in oncology, including targeting the colony-stimulating factor 1 receptor (CSF1R), today announced that the U.S. Food and Drug Administration (FDA) has granted AMB-05X Fast Track designation for the treatment of tenosynovial giant cell tumor (TCGT).

89bio, Inc. announced that Company’s Management will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12, 2022 at 4:00 PM ET.